Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection
- PMID: 29359013
- PMCID: PMC5756719
- DOI: 10.4254/wjh.v9.i36.1305
Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection
Abstract
Present study outlines a comprehensive view of published information about the underlying mechanisms operational for progression of chronic hepatitis C virus (HCV) infection to development of hepatocellular carcinoma (HCC). These reports are based on the results of animal experiments and human based studies. Although, the exact delineated mechanism is not yet established, there are evidences available to emphasize the involvement of HCV induced chronic inflammation, oxidative stress, insulin resistance, endoplasmic reticulum stress, hepato steatosis and liver fibrosis in the progression of HCV chronic disease to HCC. Persistent infection with replicating HCV not only initiates several liver alterations but also creates an environment for development of liver cancer. Various studies have reported that HCV acts both directly as well as indirectly in promoting this process. Whereas HCV related proteins, like HCV core, E1, E2, NS3 and NS5A, modulate signal pathways dysregulating cell cycle and cell metabolism, the chronic infection produces similar changes in an indirect way. HCV is an RNA virus and does not integrate with host genome and therefore, HCV induced hepatocarcinogenesis pursues a totally different mechanism causing imbalance between suppressors and proto-oncogenes and genomic integrity. However, the exact mechanism of HCC inducement still needs a full understanding of various steps involved in this process.
Keywords: Core; Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; Inflammation; NS5A.
Conflict of interest statement
Conflict-of-interest statement: The authors declare here that there is no conflict of interest related to this study among them.
Figures

Similar articles
-
Viral hepatitis and liver cancer: the case of hepatitis C.Oncogene. 2006 Jun 26;25(27):3834-47. doi: 10.1038/sj.onc.1209562. Oncogene. 2006. PMID: 16799625 Review.
-
Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways.J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S108-11. doi: 10.1111/j.1440-1746.2006.04669.x. J Gastroenterol Hepatol. 2007. PMID: 17567457 Review.
-
[Hepatitis C virus infection and hepatocarcinogenesis].Orv Hetil. 2010 Sep 19;151(38):1524-9. doi: 10.1556/OH.2010.28946. Orv Hetil. 2010. PMID: 20826376 Review. Hungarian.
-
Comparative analysis of viral protein interaction networks in Hepatitis B virus and Hepatitis C virus infected HCC.Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):271-9. doi: 10.1016/j.bbapap.2013.06.002. Epub 2013 Jun 14. Biochim Biophys Acta. 2014. PMID: 23774196
-
Oncogenic potential of hepatitis C virus proteins.Viruses. 2010 Sep;2(9):2108-2133. doi: 10.3390/v2092108. Epub 2010 Sep 27. Viruses. 2010. PMID: 21994721 Free PMC article.
Cited by
-
Iron at the Interface of Hepatocellular Carcinoma.Int J Mol Sci. 2021 Apr 15;22(8):4097. doi: 10.3390/ijms22084097. Int J Mol Sci. 2021. PMID: 33921027 Free PMC article. Review.
-
DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma.Mol Med Rep. 2019 Sep;20(3):2519-2532. doi: 10.3892/mmr.2019.10487. Epub 2019 Jul 11. Mol Med Rep. 2019. PMID: 31322223 Free PMC article.
-
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.Front Pharmacol. 2022 Mar 24;13:821344. doi: 10.3389/fphar.2022.821344. eCollection 2022. Front Pharmacol. 2022. PMID: 35401182 Free PMC article. Review.
-
Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma.Infect Drug Resist. 2021 Dec 7;14:5199-5208. doi: 10.2147/IDR.S337647. eCollection 2021. Infect Drug Resist. 2021. PMID: 34908854 Free PMC article.
-
A Longitudinal Analysis of Mortality Related to Chronic Viral Hepatitis and Hepatocellular Carcinoma in the United States.Viruses. 2024 Apr 28;16(5):694. doi: 10.3390/v16050694. Viruses. 2024. PMID: 38793576 Free PMC article.
References
-
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. - PubMed
-
- Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–364. - PubMed
-
- Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35–47. - PubMed
-
- Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174–181. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources